CTRI/2018/03/012340尚未招募2 期
A phase II study to assess the feasibility of involved siteradiotherapy for consolidation after chemo-immunotherapyin newly diagnosed patients of stage I-II nodal diffuse largeB-cell lymphoma
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. ECOG performance status 0-3
- •2. Biopsy proven diffuse large B-cell lymphoma
- •3. Stage I-II nodal disease as per Ann Arbor staging
- •4. Immunocompetent status (HIV sero-negative)
- •5. Absence of irreversible end-organ dysfunction
- •6. Baseline investigations within acceptable limit
- •7. Informed consent
排除标准
- •1. ECOG performance status 4
- •2. Immune-compromised status.
- •3. Any prior cancer related treatment with surgery, chemotherapy or radiotherapy
- •4. Any co-morbidity which could potentially compromise chemo-immunotherapy and radiotherapy treatment schedule
研究者
相似试验
进行中（未招募）
1 期
An investigation of the feasibility of using a topical formulation of lidocaine (SHACT) for hysteroscopy in women.Investigating the feasibility of using a topical formulation.MedDRA version: 16.0Level: PTClassification code 10064882Term: Procedural painSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2013-001775-20-SEPharmanest AB10
尚未招募
不适用
A study investigating the feasibility of stereotactic radiotherapy for the palliation of Head and Neck CancerHead and Neck CancerCancer - Head and neckACTRN12621001548820South Western Sydney Local Health District40
招募中
2 期
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL10025320lymphomaNL-OMON36830HOVO60
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation - HOVON 80 NHrelapsed B cell lymphomaMedDRA version: 8.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2006-002141-37-NLHOVON foundation35
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLMedDRA version: 14.1Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-007083-28-NLHOVON foundation60